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Identity 
Hugo: PTGS2 
Other names: COX2 (Cyclooxygenase 2); COX-2; 
PGG/HS; PGHS-2; PHS-2; hCox-2 
Location: 1q31.1 
DNA/RNA 
Description 
8633 bases, 10 exons. 
Transcription 
One transcript (chr1:184907546-184916179). COX2 
promoter is regulated via the interplay between two 
opposite beta isoforms of the CCAAT/enhancer 
binding protein and the p300 coactivator. 
Protein 
Description 
COX2 is an enzyme that belongs to the prostaglandin 
G/H synthase family. It consists of 604 amino acids and 
has a molecular weight of 68996 Da. 
COX2 possesses two catalytic activities and respective 
active sites:  
- a cyclooxygenase (COX) that converts arachidonic 
acid to a prostaglandin endoperoxide, prostaglandin G2 
(PGG2), and; 
- a peroxidase (POX) that reduces PGG2 to PGH2. 
COX2 functions as homodimer although each subunit 
has both a POX and a COX active site. 
 
Each subunit binds one heme B (iron-protoporphyrin 
IX) group. 
Expression 
Wide expression in alimentary system (esophagus, 
pharynx), male reproductive system (prostate, seminal 
vesicles, ejaculatory duct), female reproductive system 
(cervix, uterus), hematopoietic system (bone marrow, 
monocytes). 
Localisation 
Intracellular, cytoplasm, microsome, microsomal 
membrane. 
Function 
Enzyme that functions both as a dioxygenase and as a 
peroxidase. COX-2 catalyzes the transformation of 
arachidonic acid to prostaglandin H2, which is the rate-
limiting step in the formation of prostaglandins (PGs) 
and thromboxane A2 (TXA2). COX-2 is a potent 
mediator of inflammation and is implicated in 
prostanoid signaling in activity dependent plasticity. It 
is an inducible enzyme that plays an important role in 
several pathophysiological processes, including 
inflammation, angiogenesis, and tumorigenesis. 
Mutations 
Note: Five heterozygous mutations (1 
missense/nonsense, 1 splicing, 3 regulatory) have been 
identified. Two were associated with diabetes mellitus 
type 2, one with bladder cancer risk, one with increased 
risk of colorectal cancer and one with decreased risk of 
colorectal cancer. 
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Implicated in 
Colorectal cancers 
Disease 
COX2 is involved in regulation of apoptosis, 
proliferation and invasiveness of colorectal tumor cells 
and promotes angiogenesis in several animal colon 
cancer models. It is also implicated in several 
premalignant lesions including adenomatous polyps. 
COX2 stimulates colon cancer cell growth through its 
heterotrimeric guanine nucleotide-binding protein (G 
protein)-coupled receptor, EP2. 
Gastric cancer 
Disease 
Expression of COX2 is elevated in gastric 
adenocarcinomas, which correlates with several 
clinicopathological parameters, including depth of 
invasion and lymph node metastasis. 
Non small cell lung cancer 
Disease 
Non-small-cell lung cancer (NSCLC),  
especially adenocarcinomas, overexpress COX2, which 
contributes to the progression of malignancy by several 
mechanisms. 
Cholangiocarcinoma 
Disease 
COX2 has been implicated in cholangiocarcinogenesis. 
Selective COX-2 inhibitors have been shown to inhibit 
cholangiocarcinoma cell growth in vitro and in animal 
models. 
Uterine carcinosarcoma 
Disease 
COX2 is overexpressed in one-third of uterine 
carcinosarcomas. COX-2 expression is a strong 
indicator of unfavorable prognosis. 
Head and Neck squamous cell cancer 
Disease 
COX2 is overexpressed in a variety of premalignant 
and malignant conditions, including oral leukoplakia 
and squamous cell carcinoma of the head and neck. 
Ovarian cancer 
Disease 
COX-2 is increased in epithelial ovarian cancer and 
PGE2-synthesis and signalling are important for 
malignant transformation and progression. 
Pancreatic cancer 
Disease 
Mounting evidence suggests that COX2 is implicated 
in pancreatic cancer. 
Immunohistochemical, RT-PCR, and Western blotting 
studies have shown that COX2, is upregulated in 
human pancreatic cancer cell lines as well as human 
pancreatic cancer tissues compared with normal ductal 
cells and normal pancreas specimens. COX2 inhibitors 
significantly inhibit pancreatic cancer growth both in 
vitro and in vivo while simultaneously induce 
apoptosis. 
Other malignant diseases 
Disease 
Similar to above tumors, COX2 is implicated in 
carcinogenesis of multiple tumors including transitional 
cell bladder cancer, prostate cancer, uterine cancer, 
cervical cancer, angiosarcoma, hepatocellular cancer, 
melanoma, multiple myeloma, chronic lymphocytic 
leukemia, thyroid cancer, Wilms tumor. 
Primary dysmenorrhea 
Disease 
In vivo studies have demonstrated that selective COX-2 
inhibitors are effective in treatment of primary 
dysmenorrhea in women. 
Inflammatory conditions 
Disease 
COX2 occupies an important in several inflammatory 
diseases such as osteoarthritis and rheumatoid arthritis. 
Neurolomuscular disorders 
Disease 
COX2 is implicated in encephalitis, cerebral infarction, 
polyneuropathy and muscular dystrophies. 
Cardiovascular toxicity and 
thromboembolic disorders 
Note: Selective inhibition of COX2 (without 
concomitant inhibition of COX1) is associated with 
significant cardiovascular risk and thromboembolic 
phenomena. 
Retinopathy 
Disease 
COX2 plays an important role in ischemic proliferative 
retinopathy, as in the case of diabetic retinopathy. 
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